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Abstract The inverse relationship between high density lipo-
protein (HDL) plasma levels and coronary heart disease has
been attributed to the role that HDL and its major constitu-
 
ent, apolipoprotein A-I (apoA-I), play in reverse cholesterol
transport (RCT). The efficiency of RCT depends on the spe-
cific ability of apoA-I to promote cellular cholesterol efflux,
bind lipids, activate lecithin:cholesterol acyltransferase
(LCAT), and form mature HDL that interact with specific
receptors and lipid transfer proteins. From the intensive
analysis of apoA-I secondary structure has emerged our cur-
rent understanding of its different classes of amphipathic
 
a
 
-helices, which control lipid-binding specificity. The main
challenge now is to define apoA-I tertiary structure in its
lipid-free and lipid-bound forms. Two models are consid-
ered for discoidal lipoproteins formed by association of
two apoA-I with phospholipids. In the first or picket fence
model, each apoA-I wraps around the disc with antiparallel
adjacent 
 
a
 
-helices and with little intermolecular interac-
tions. In the second or belt model, two antiparallel apoA-I
 
are paired by their C-terminal 
 
a
 
-helices, wrap around the
lipoprotein, and are stabilized by multiple intermolecular in-
teractions. While recent evidence supports the belt model,
other models, including hybrid models, cannot be ex-
cluded. ApoA-I 
 
a
 
-helices control lipid binding and associa-
tion with varying levels of lipids. The N-terminal helix 44–
65 and the C-terminal helix 210–241 are recognized as im-
portant for the initial association with lipids. In the central
domain, helix 100–121 and, to a lesser extent, helix 122–
143, are also very important for lipid binding and the for-
mation of mature HDL, whereas helices between residues
144 and 186 contribute little. The LCAT activation domain
has now been clearly assigned to helix 144–165 with second-
ary contribution by helix 166–186. The lower lipid binding
affinity of the region 144–186 may be important to the acti-
vation mechanism allowing displacement of these apoA-I
helices by LCAT and presentation of the lipid substrates.
No specific sequence has been found that affects diffu-
sional efflux to lipid-bound apoA-I. In contrast, the C-terminal
helices, known to be important for lipid binding and main-
tenance of HDL in circulation, are also involved in the inter-
action of lipid-free apoA-I with macrophages and specific
lipid efflux. While much progress has been made, other as-
pects of apoA-I structure–function relationships still need
to be studied, particularly its lipoprotein topology and its in-
teraction with other enzymes, lipid transfer proteins and re-
 
ceptors important for HDL metabolism.
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This review focuses on the identification of apoA-I
structural domains and their participation to HDL RCT.
We will summarize the current knowledge on apoA-I
structural domains and more particularly their function in
lipid binding and formation of HDL, their contributions
to cellular cholesterol efflux, and their role in LCAT acti-
vation. In each case, a particular emphasis will be placed
on the study of apoA-I mutants and the analysis of struc-
tural and functional domains.
 
1. APOLIPOPROTEIN A-I STRUCTURE
AND HDL FORMATION
Apolipoprotein A-I was one of the first apolipoproteins
to be identified and characterized. Yet its structural char-
acterization, notably in the lipid-associated form, has not
been achieved and the domains involved in its multiple
functions are not yet fully identified.
 
A. Primary structure and physicochemical
properties of apoA-I
 
The sequence of apoA-I was determined by Brewer et
al. (1), and followed by cloning and characterization of its
cDNA (2–5) and genomic DNA (6, 7). The gene encod-
ing apoA-I is a member of the apolipoprotein multigene
superfamily, which includes genes encoding exchange-
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able apolipoproteins (apoA-I, A-II, Cs, and E) (8). They
are thought to have evolved from a common ancestor by
duplication/deletion of a 33-mer motif.
Analysis of the secondary structure of mature apoA-I
has allowed the identification of 11- and 22-mer repeats
(9, 10). The 22-mer repeats, usually separated by Pro resi-
dues, have been associated with the formation of amphi-
pathic 
 
a
 
-helices (11), which allow the interaction of the
protein with phospholipids through its hydrophobic face,
while the hydrophilic face of the helices interacts with the
aqueous phase.
ApoA-I sequences from a number of species have been
determined (
 
Fig. 1
 
), with sizes ranging between 258 and
267 amino acids (mature protein plus pre-pro segment).
Comparison of sequences amongst mammals indicates
that the N-terminal domain of apoA-I is highly conserved
while the central and C-terminal domains show conserva-
tive substitutions between species. This result is consistent
with the study of Collet et al. (12), who showed, using
mAbs to human apoA-I, that the antigenicity of this pro-
tein is better conserved between species in the N-terminal
domain (residues 1 to 98 of the mature protein). These
observations are in accord with the major role this do-
main plays in the structure and/or function of human
apoA-I. As described in the latter sections of this review,
the N- and C-terminal domains of apoA-I have been in-
volved in the binding of lipids, an essential function of
this apolipoprotein (13–15). The central domain of the
protein, which has been involved in LCAT activation, may
have evolved in parallel with the LCAT sequence in the
corresponding species. However, in species in which this
domain has evolved faster than in humans (mouse and
rat), the ability of mouse apoA-I to activate mouse LCAT is
reduced as compared to that of human apoA-I (16, 17).
Despite changes in the primary structure of apoA-I amongst
different species, the secondary structure appears unmod-
ified, as shown by the Edmundson-wheel representation
(12). Studies by Januzzi et al. (18) suggest that apoA-I has
evolved about 25% faster than an average gene in mam-
malian lineage. However, all portions of the protein have
evolved at similar rates, which suggests a global conserva-
tion of the structure.
ApoA-I is known to self-associate, a process which may
stabilize the lipid-free protein. However, at low concentra-
tions (below 0.1 mg/ml) (19), or in the presence of
guanidine hydrochloride (GdnHCl) (20), only the mono-
meric form is detected. Denaturation studies have indi-
cated a midpoint of denaturation close to 1 
 
m
 
 GdnHCl for
the lipid-free form of apoA-I (20, 21), and an increased
stability in the presence of phospholipid (21, 22). In Gdn-
 
HCl, urea, or calorimetric denaturation experiments, a
low free energy of denaturation about 2.2–2.7 kcal/mol
has been determined (22, 23). This value is much lower
than the value determined for globular proteins (in the
range of 5–10 kcal/mol) (24, 25). This observation is in
agreement with a loosely folded and relatively flexible
structure of the protein in the lipid-free form. This loosely
folded conformation may allow rapid lipid-interaction of
exposed hydrophobic portions of the protein. In support
of this view, thermal denaturation experiments by Gursky
and Atkinson have suggested a molten globular-like state
for lipid-free apoA-I that may explain its lipid-binding
properties in vivo (26). Sedimentation velocity experi-
ments on human apoA-I indicate significant conforma-
tional heterogeneity, which also support a flexible struc-
ture (27). This observation may be relevant in the case of
pre
 
b
 
1
 
-HDL, which has been shown to be the earliest ac-
ceptor of cellular cholesterol (28) and appears to contain
only 1–2 molecules of partially lipidated apoA-I (29). The
N-terminal sequence (residues 1–43) of apoA-I, appar-
ently not required for lipid binding, may be important for
the stabilization of lipid-free apoA-I in solution (30, 31).
Site directed mutagenesis of tryptophans and fluores-
cence studies show that in the lipid-free state the apoA-I
monomer is a prolate ellipsoid and its tryptophans exist in
nonpolar environments compatible with an N-terminal
half that is organized into a bundle of helices (32).
Two cysteine mutants (D9C and A232C) have been
studied by circular dichroism and fluorescence spectro-
photometry. The adduct formed with the thiol reactive
probe acrylodan affects the structure and stability of the
lipid-free D9C mutant but not that of the mutant A234C.
The fluorescence analysis showed rigid N- and C-terminal
structures of the lipid-free apoA-I and a fold that brings
the C-terminus close to the tryptophans of the N-terminal
half (33).
 
B. Role of amphipathic 
 
a
 
-helices in the
interaction of apoA-I with lipids
 
Algorithms allowing the prediction of the secondary
structure of proteins (34, 35) suggest that apoA-I may be
composed of 8–9 
 
a
 
-helices formed essentially by the 22-
mer repeats, with a less well-defined N-terminal secondary
structure (
 
Fig. 2
 
) (reviewed in ref. 36). These predictions
were partially confirmed by experimental data using CD
and IR spectroscopy to determine the total 
 
a
 
-helicity of
apoA-I (37–39). Investigations using tryptophan fluores-
cence to examine the change in apoA-I conformation ob-
served upon association with lipids led to similar conclu-
sions (37, 40).
 
Fig. 1.
 
Sequence comparison between apoA-I from 11 species. Human (2), baboon (198), dog (199), pig (200), rabbit (201), cow (202),
hedgehog (203), mouse (204), rat (205) chicken (206), duck (Swiss-Prot accession number, O42296), and salmon (207) apoA-I sequences
are presented in decreasing order of their similarity to human apoA-I. Blanks indicate identity to human apoA-I; dashes ( –) indicate dele-
tions inserted to maximize homology between sequences. The pre-pro sequence of dog apoA-I has not been determined. Colors indicate
proline (purple, P); aspartic acid or glutamic acid (red, D and E); arginine or lysine (blue, R or K); and phenylalanine, isoleucine, leucine,
methionine, valine, tryptophan, or tyrosine (green, F, I, L, M, V, W, and Y). The remaining amino acids, alanine, cysteine, glycine, histidine,
asparagine, glutamine, serine, and threonine (A, C, G, H, N, Q, S, and T) are uncolored and called indifferent (8). The numbering of
human apoA-I starts at 
 
2
 
24 (signal peptide of apoA-I), residue 1 being the first one of mature apoA-I.
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Mode of interaction with lipids.
 
Early studies have shown
that isolated apoA-I can spontaneously interact with
dimyristoyl phosphatidylcholine (DMPC) at its transition
temperature (41–43) and form discoidal complexes (44).
Reassembly of discoidal HDL and their conversion to
spheres by the action of LCAT was first demonstrated by
Forte et al. (45). Several groups have also shown that the
binding of apoA-I to egg phosphatidylcholine or palmitoy-
loleyl phosphatidylcholine (POPC), in the presence of the
detergent sodium cholate, resulted in the formation of
discoidal lipoproteins (46, 47). The formation of spheri-
cal complexes could be obtained by incubation of LCAT
and LDL, as a FC donor, with discoidal complexes (40,
45, 48, 49) or by co-sonication of a lipid–apoA-I mixture
(50, 51).
A mechanism to explain the mode of apoprotein associ-
ation with the lipid surface was proposed by Segrest et al.
(52), who first suggested the existence of amphipathic
 
a
 
-helices in apolipoproteins. The involvement of 
 
a
 
-helices
in the binding of phospholipid was demonstrated by mea-
suring the change in the ellipticity at 222 nm after bind-
ing of the apoprotein to phospholipid. Lipid-free apoA-I
typically exhibits an 
 
a
 
-helix content of 40–50% while in
association with phospholipid the 
 
a
 
-helicity increases to
 
,
 
75% depending on the type of lipids and complexes
formed (22, 37). This property is also shared by other apo-
lipoproteins and suggests a very similar mechanism of as-
sociation with lipids for all exchangeable apolipoproteins.
ApoA-I immunoreactivity toward mAbs has also been
shown to be altered by the presence of lipids (53, 54),
which indicates important conformational changes affect-
ing most domains upon association with lipids.
The Edmundson wheel representation gives some hints
as to how charged residues affect the affinity of an 
 
a
 
-helix.
Segrest and colleagues (11) proposed that 
 
a
 
-helices of
apolipoproteins are not all equivalent for their affinity to-
wards lipids. The differences in affinity do not appear to
be simply related to their hydrophobic moment but also
to the distribution of charge residues along the axis of the
helix. Computer analysis of the different classes of amphi-
pathic helices has led to a classification of the physico-
chemical properties associated with each class (11). Am-
phipathic 
 
a
 
-helices of apolipoproteins form the class A.
Classes L, H, M, and G have been used to identify lytic,
hormone, transmembrane, and globular amphipathic
 
a
 
-helices, respectively. Class A is characterized by a high
mean hydrophobic moment and by its unique charge dis-
tribution: positively charged residues are clustered at the
polar–nonpolar interface, whereas negatively charged
residues are found at the center of the polar face. For
apoA-I, 6 helices have been identified with this specific
amino acid distribution (helices 44–65, 66–87, 121–142,
143–164, 166–186, 187–208). Two other types of helices
have been identified: class G* (helix 8–33) and class Y
(helices 88–98, 99–120, 209–219, 220–241) (
 
Fig. 3
 
), each
characterized by a specific charge distribution (11). These
different helices may have different structural functions
and lipid-binding properties but we still have a poor un-
derstanding of these relationships in apoA-I. Segrest et al.
(11) had proposed that class Y had a reduced lipid affinity
but, as it will be discussed below, helix 220–241 has the
highest affinity for lipids amongst apoA-I 
 
a
 
-helices (13).
In class A amphipathic 
 
a
 
-helices, the importance of the
charge distribution has been examined with synthetic
peptides with positively charged residues clustered at the
polar–nonpolar interface and negatively charged residues
at the center of the polar face. A decreased affinity for lip-
ids was observed for peptides with a reverse charge distri-
bution (55–57). The snorkel model of Segrest and col-
leagues (11) proposes that the positively charged residues,
which are also amphipathic and have their long alkyl
chain buried in the hydrophobic interior, extend (“snor-
kel”) toward the polar face of the helix to insert their pos-
itive moieties into the aqueous phase. Recently, Lecompte
et al. (58) have studied the steps in the binding of apoA-I
to phospholipid monolayers, using alternative current po-
larography. This novel application of the technique iden-
tified two steps, adsorption and penetration, and sup-
ported the snorkel model (11).
The properties of synthetic peptides that correspond to
each of the predicted apoA-I helical segments have been
recently examined (13). Only peptides corresponding to
helices 44–65 and 220–241 have been found to associate
with lipids with a significant affinity. This result has been
attributed to a deeper penetration of these two helices
into the lipid interface, as compared to other helices. He-
lices 44–65 and 210–241 also present a higher total hy-
drophobicity on the nonpolar face. Although these iso-
lated helices have faster kinetics of association with DMPC
than apoA-I as a whole molecule, apoA-I can however re-
duce the enthalpy of the gel-to-liquid crystalline phase
transition much more effectively, possibly due to the coop-
Fig. 2. Mode of interaction of apoA-I with phospholipids: picket
fence model on a discoidal particle. The disc formed by a phospho-
lipid bilayer can accommodate apoA-I amphipathic a-helices, paral-
lel to the phospholipid acyl chains. In small discoidal LpA-I (apoA-I-
containing lipoproteins), two helices do not interact with the lipid
interface possibly because of a reduced affinity for lipids (A). How-
ever, in large discoidal LpA-I (B), these helices, which have been
termed a hinge domain, interact with lipids and can therefore allow
one molecule of apoA-I to associate with varying amounts of lipid.
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erativity between central 
 
a
 
-helices (13). It has therefore
been suggested that the two extreme helices of apoA-I
may initiate the binding to phospholipid, followed by a
cooperative binding of the other helices (13). This co-
operativity may be facilitated by antiparallel helix–helix
salt-bridges and by hydrogen bond interactions (59, 60).
However, studies by Mishra et al. (14), comparing tandem
and the constituent helices did not show any evidence of
 
this cooperativity. This has first been interpreted as indica-
tions that peptides of different length cannot be directly
compared and second that cooperativity effectively inter-
venes when the peptide is longer. Cooperativity may there-
fore be associated with a more complex tertiary structure
of apoA-I that is yet to be determined. Alternatively, tan-
dem helices may help in the stabilization of the lipopro-
tein complexes formed, avoiding their reorganization. In
fact, in a recent in vitro study, we have shown that, in the
central domain of apoA-I, the helix formed by residues
100–121 is very important for the stabilization of the lipid-
apolipoprotein complex, while helices spanning residues
122–186 contribute to the initial rates of lipid-apolipopro-
tein association (61). Pro, present at the first position of
almost every 22-mers (by comparison, helices of trans-
membrane proteins have approximately 20 amino acid
residues) (62), often form 
 
b
 
-turns or kinks between helices
and are therefore essential for the secondary structure of
apolipoproteins. The presence of a Pro residue appears
necessary in defining the structural and functional prop-
erties of apoA-I, which associates mostly with small lipo-
proteins (HDL). In contrast, the apoE lipid-binding domain
contains a 65-mer helix and, consequently, associates also
with larger lipoproteins (11).
 
Structure of apoA-I on model lipoproteins.
 
ApoA-I can form
discoidal as well as spherical complexes, depending on
the conditions of association. In vitro reconstituted discoi-
dal LpA-I complexes usually have a pre
 
b
 
-HDL migration on
agarose gel electrophoresis and change to an 
 
a
 
-mobility fol-
lowing incubation with plasma factors (d 
 
.
 
 1.21 g/ml) or
LCAT alone (48). Discoidal LpA-I complexes can contain
two, three, or more molecules of apoA-I per particle (37).
As already indicated, increasing the POPC content of re-
constituted discoidal LpA-I leads to an increase in the
 
a
 
-helical content of apoA-I (37, 39). It also leads to reduced
protease accessibility suggesting a major conformational
change upon association with lipids (30, 63). Studies from
our laboratory using mAbs as conformational probes have
also indicated that apoA-I undergoes major conforma-
tional changes upon lipid binding (53, 54, 64). In the case
of discoidal complexes, specific domains are affected with
increased phospholipid or cholesterol content, i.e.,
changes in epitope accessibility are mostly observed in the
central (residues 99–148) and N-terminal domain (resi-
dues 2–8). Interestingly, the changes in immunoreactivity
are in the opposite direction (i.e., central and N-terminal
epitopes become less immunoreactive with increasing
phospholipid and more immunoreactive with increasing
cholesterol) (64).
The most studied and best-characterized model of
apoA-I interaction with lipids remains the discoidal com-
plex that will be discussed here. Several secondary struc-
ture models of apoA-I on discs have been suggested (36,
39, 41, 54, 65–67). In the first models, eight antiparallel
amphipathic 
 
a
 
-helices connected by 
 
b
 
-turns have been
proposed to interact in parallel to the phospholipid acyl
chains (Fig. 2). These models were derived from investiga-
tions that combined secondary structure prediction meth-
ods and biophysical methods (39, 66, 67) or mAb immu-
Fig. 3. Edmundson wheel representation of apoA-I a-helices. Col-
ors indicate proline (purple, P); aspartic acid or glutamic acid (red,
D and E); arginine or lysine (blue, R or K); and phenylalanine, iso-
leucine, leucine, methionine, valine, tryptophan, or tyrosine
(green, F, I, L, M, V, W, and Y). The remaining amino acids, ala-
nine, cysteine, glycine, histidine, asparagine, glutamine, serine, and
threonine (A, C, G, H, N, Q, S, and T) are uncolored and called in-
different (8). The class of amphipathic helices (A, Y) to which each
helix belongs is also indicated.
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noreactivity studies (54). Several of these models suggest
the existence of a hinge domain that may be responsible
for the ability of apoA-I to associate with lipoprotein com-
plexes of different sizes (37). This putative domain at first
tentatively identified as either aa 100–143 or aa 122–165
(54), may be excluded from the interaction with lipid in
small discoidal LpA-I, whereas it may participate in the in-
teraction with phospholipid in large discoidal LpA-I (Fig.
2). Recent studies from this laboratory have indicated that
the plasticity of the central domain of apoA-I (residues
100–186) is essential for the ability of apoA-I to associate
with varying amounts of phospholipid (61). Protease ac-
cessibility studies performed with lipidated apoA-I have
provided data that are consistent with this view and have
identified a domain that is more sensitive to protease di-
gestion in the central region of apoA-I in small LpA-I com-
plexes (63).
Based on anti-apoA-I mAb competition for binding to
a discoidal Lp2A-I, Bergeron et al. (64) suggested that
the two apoA-I molecules be organized in a head-to-tail
configuration. Another interesting conclusion emerging
from these antibody competitions on models of discoi-
dal Lp2A-I is the notion that the N-terminal domain of
apoA-I may interact with the central domain of the pro-
tein, especially in small Lp2A-I (39, 54, 64). In contrast,
a computer generated model of discoidal Lp2A-I from
Phillips et al. (68) suggested that both the head-to-tail
and the head-to-head conformations may coexist, since
 
no particular configuration was favored. However, Phil-
lips et al. (68) could not integrate residues 1 –47 in their
model, and this region has been shown to contribute
significantly to the overall structure of apoA-I (39, 54,
64). Recently, fluorescence studies of cysteine mutants
have shown that in discoidal Lp2A-I particles the C-ter-
minal cysteine is close to the N-terminal tryptophans,
thus excluding the possibility of a head-to-head picket
fence configuration (33).
 
Crystal structure of apoA-I.
 
Borhani et al. (69, 70) have
recently determined the crystal structure of a truncated
lipid-free form of apoA-I (lacking residues 1–43 or apoA-
I
 
D
 
(1–43)). In its lipid-free form in the crystal unit, the
mutant protein appears to exhibit a conformation simi-
lar to that of lipid-bound apoA-I (31), a characteristic,
which justifies its discussion in the context of the struc-
ture of lipid-bound apoA-I. This protein appears as an el-
liptical ring-like structure consisting of four molecules of
the apoprotein. These four molecules associate via the
hydrophobic faces of their amphipathic helices to form a
four-helix bundle (
 
Fig. 4
 
). Crystallization of the 22 kDa
N-terminal fragment of apoE also showed that this frag-
ment can adopt a helical bundle conformation that com-
prises 4 
 
a
 
-helices arranged with their hydrophobic faces
brought together towards the center of the molecule
(71). Similarly, the structure observed for apolipophorin
III, an insect apolipoprotein, was also shown to be a heli-
cal bundle (72). These two structures are distinctly dif-
Fig. 4. Ribbon representation of the crystallized tetramer of apoA-ID(1–43). The elliptical and curved shape of the protein is evident from
this structure. A, B, C, and D represent four different views of the same structure along different axes. Molecule A is gold, B is purple, C is
pink, and D is green. Note the antiparallel orientation of molecules A and B, and C and D. The A/B dimer and the C/D dimer are also ori-
ented in an antiparallel manner (70).
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ferent from that of apoA-I
 
D
 
(1–43) in that they represent
intramolecular bundles whereas the apoA-I
 
D
 
(1–43)
structure is an intermolecular bundle. The asymmetric
unit of the mutant apoA-I structure contains two dimers,
each constituted by a pair of antiparallel monomers of
similar but unique conformations (
 
Fig. 5
 
). The antipar-
allel arrangement of the monomers brings the N-termi-
nal and C-terminal helices of each molecule in close
proximity (Fig. 5). In this crystal structure, the predicted
punctuations of the 10 helices by the Pro and Gly resi-
dues are not 
 
b
 
-turns but rather kinks occurring at these
residues within the ellipsoid helical ring of each mono-
mer. Borhani and colleagues (70) also proposed a model
of a spherical HDL containing four apoA-I molecules.
The spherical HDL has an ellipsoidal shape, which ac-
commodates apoA-I in a belt mode. A model for discoi-
dal HDL was also proposed (70), and according to this
model, apoA-I may wrap around the edge of the disc
with its 
 
a
 
-helices oriented perpendicular to the phospho-
lipid acyl chains. This model is not, however, consistent
with some early results obtained by attenuated total re-
flection infrared spectroscopy that have shown that, in a
disc, apoA-I 
 
a
 
-helices are, rather, oriented parallel to the
phospholipid acyl chain (38, 73). More recent analysis
using polarized attenuated total internal reflection (PATIR)
infrared spectroscopy has challenged this interpretation
(74). The orientation of apoA-I on discoidal particles
was examined under native conditions by adsorption of
 
Lp2A-I particles to a phospholipid monolayer using
phosphatidylserine incorporated in both the monolayer
and the lipoprotein and Ca
 
2
 
1
 
 as linkers. Under these
conditions, Koppaka and colleagues (74) concluded that
apoA-I helices are oriented perpendicular to the acyl
chains of phospholipids and unambiguously supported a
belt-model structure. The belt structure may be similar
to that observed in spherical HDL (70), and, in that case,
the N-terminus may modulate apoA-I conformation by
directly interacting with the central domain of the pro-
tein (22, 54).
 
Lessons learned from biophysical techniques.
 
In summary,
many studies of apoA-I structure on model discoidal lipo-
proteins support the notion of a central hinge domain
that is loosely bound to lipids and separates the N-termi-
nal and C-terminal domains. These studies also generally
favor the antiparallel configuration of adjacent amphi-
pathic helices, which came to be known as the picket fence
model. However, this model has now been challenged by
the belt structure that is supported by the crystal structure
of lipid-free apoA-I
 
D
 
(1–43) (70) and by the PATIR infra-
red spectroscopy of discoidal Lp2A-I cited above (74). Re-
cently, Davidson has measured the orientation of one of
apoA-I central helices in discoidal particles using nitroxide
spin label-induced quenching of tryptophan fluorescence
to determine the depth of helix 4 (residues 100–121) in
the bilayer of the disc. The results also demonstrate that
helix 4 is perpendicular to the acyl chains, an orientation
Fig. 5. Ribbon representation of two monomers of apoA-ID(1–43). The two basic constituents of a dimer
of apoA-ID(1–43) are represented. The N- and C-terminals of each monomer are labeled as well as the first
residues of each identified helix (70). 1av1 chains A and B refer to the PDB identification codes given by the
Brookhaven protein structure database (address on the world wide web: http://www.rcsb.org/pdb/). This
edited version was obtained by courtesy of Drs. David Borhani and Christie Brouillette.  at Thom
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compatible with the belt model (S. Davidson, unpub-
lished results). Recently, computer-modeling studies per-
formed by Segrest et al. (75) have suggested a model of
discoidal complexes in which 2 molecules of apoA-I inter-
act in an antiparallel manner and wrap around the phos-
pholipid bilayer following a belt. Interestingly, this model
also matches the crystal structure of the lipid-free apoA-
I
 
D
 
(1–43) (70).
It is difficult to definitively conclude which model struc-
ture is correct and whether the belt or antiparallel models
are mutually exclusive or can exist in different settings,
i.e., in spherical or discoidal lipoproteins. The weight of
recent evidence favors the belt structure where the amphi-
pathic helices are perpendicular to the acyl chains. How-
ever, hybrid structures where some or most of the helices
are perpendicular to the acyl chains cannot be excluded
at this time.
 
C. ApoA-I mutagenesis and the definition 
of lipid binding domains
 
In the following section, we will analyze and compare
the properties of both natural and engineered apoA-I vari-
ants that have been described, and for which, at least a
partial lipoprotein phenotype and/or apoA-I structure–
function characterization has been performed (
 
Table 1
 
).
We will also attempt to correlate the in vivo observations
with the in vitro functional apoA-I characterizations, includ-
ing the works performed using site directed mutagenesis of
apoA-I. To facilitate the reading, apoA-I mutagenesis is di-
vided in three sections covering the N-terminal, central,
and C-terminal domains, normally recognized in the pro-
tein. However, the reader should be cautioned that the
delineation of such domains remains somewhat arbitrary.
 
Mutations of the N-terminal domain.
 
Several naturally oc-
curring mutations in the N-terminal domain have been
 
TABLE 1 Characterizations of naturally occurring apoA-I mutations
 
Functional and Clinical Consequences
Mutation Lipid-binding
Cholesterol 
Efflux
LCAT 
Activation HDL/A-I Levels Comments References
 
Pro
 
3
 
Ý
 
Arg normal normal impaired pro apoA-I
conversion
76, 172
Pro
 
3
 
Ý
 
His normal normal impaired pro apoA-I 
conversion
76, 173
Pro
 
4
 
Ý
 
Arg normal normal normal no apparent effect 76, 76, 172, 173
Arg
 
10
 
Ý
 
Leu normal (?) 174
Asp
 
13
 
Ý
 
Tyr reduced A-I levels 175
Gly
 
26
 
Ý
 
Arg amyloidosis 176
Ala
 
37
 
Ý
 
Thr normal no apparent effect 177
Trp
 
50
 
Ý
 
Arg amyloidosis 178
Leu
 
60
 
Ý
 
Arg amyloidosis 179
60–71
 
Ý
 
Val–Thr amyloidosis 180
 
D
 
(70–72) amyloidosis 181
Pro
 
90
 
Ý
 
Leu amyloid cardiomyopathy 182
Ala
 
95
 
Ý
 
Asp normal no apparent effect 183
Tyr
 
100
 
Ý
 
His normal no apparent effect 184
Asp
 
103
 
Ý
 
Asn normal no apparent effect 173
Lys
 
107
 
Ý
 
0 impaired reduced reduced 
HDL-C LpA-I: A-II
possible amyloidosis 76, 185–187
Lys
 
107
 
Ý
 
Met normal normal normal 76, 188
Trp
 
108
 
Ý
 
Arg normal no apparent effect 183
Glu
 
110
 
Ý
 
Lys normal 189
Glu
 
136
 
Ý
 
Lys normal normal apoE
 
2
 
 phenotype 190
Leu
 
141
 
Ý Arg reduced 
(plasma)
reduced reduced a-HDL CHD (other risk factors) 128, 170
Pro143Ý Arg reduced reduced A-I 191
D(146–160) impaired reduced reduced A-I 1 HDL dominant negative
phenotype
77, 192
Arg151Ý Cys reduced reduced A-I 1 HDL similar to apoA-IMilano 165
Val156Ý Glu reduced reduced corneal opacity 193
Ala158Ý Glu reduced A-I levels 194
Leu159Ý Arg normal normal reduced reduced A-I 1 HDL dominant negative 
phenotype
129, 195
Arg160Ý Leu ? reduced HDL, 
A-I, LpA-I:A-II
196
His162Ý Gln no apparent effect 184
Pro165Ý Arg normal reduced reduced reduced A-I 1 HDL 76, 172
Arg173Ý Cys impaired reduced reduced reduced A-I 1 HDL increased TG longevity 78, 81, 83–85
Arg173Ý Pro nd reduced amyloidosis 197
Glu198Ý Lys normal normal normal normal (?) 76, 92, 93, 188
Glu235Ý 0 nd reduced normal reduced faster turnover 94
Phenotype is described as well as the properties observed in vitro. Only mutations with small modification (mutants with additional residues or
with less than 90% of apoA-I sequence are not included) and for which a phenotype or functional data is available are described.
(?) indicates that reduced HDL-C levels or CHD have been associated in some patients with the mutation.
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identified and these mutations are often associated with
amyloidosis (Table 1). This disease is a disorder of protein
metabolism in which autologous proteins or their frag-
ments associate with amyloid precursor proteins and are
deposited as fibers in the tissues. Small N-terminal frag-
ments of apoA-I variants have been found in some individ-
uals with amyloidosis (Table 1). The presence of an extra
positive charge in the N-terminal domain may be responsible
for the formation of amyloid deposits. Defects in the metab-
olism of HDL resulting from mutations in the N-terminal
domain have not yet been fully elucidated.
We have studied a site–directed engineered mutant of
apoA-I lacking the domain 1–43. We have observed that
the mutant apolipoprotein remains oligomerized after in-
cubation with cholate (used to prepared discoidal com-
plexes), whereas this was not the case for apoA-I and
other deletion mutants, including those of the C-terminal
domain (Frank, P. G., C. G. Brouillette, J. A. Engler, and
Y. L. Marcel, unpublished results). Hence the N-terminal
domain is not only important in the stabilization of the
lipid-free protein (31) but may also favor the formation of
lipid–protein complexes by maintaining a certain accessi-
bility to the lipid-binding helices formed by residues 44–
65 and residues 220–241, and possibly to the central
domain. Although the domain containing helix 44–65 has
not yet been fully characterized, studies by Palgunachari
et al. (13) have indicated that it binds lipids almost as effi-
ciently as the C-terminal helix 220–241. Rogers et al. (27)
have recently examined site-directed engineered deletion
mutants of the N-terminal domain. Their studies dem-
onstrate the importance of the amino terminal 1–43 and
lack of importance of the C-terminal aa 187–243 for the
proper folding of the lipid-free protein. Moreover, they
also show the presence of conformational heterogeneity
observed for the first time for human apoA-I and the mu-
tants by sedimentation velocity experiments. The dynam-
ics and shape for these molecules provide structural infor-
mation supporting a lipid binding mechanism and
suggest a conformational flexibility that may help apoA-I
bind lipids by allowing access to hydrophobic surface of
the molecule. Deletion of residues 88–98 also resulted in
an unexpected low stability and low helicity of apoA-ID
(88–98) (5% of the residues missing results in a 50% re-
duction in helicity). Interestingly, the domain 88–98 rep-
resents one of the two 11-mer a-helices of apoA-I and may
be important in determining the proper pairing of helices
as proposed in the belt model. Work from Rogers et al.
(27) that compared D(1–43) and D(1–65) suggests that
residues 44–65 are completely helical in human apoA-I
and may be involved in the conformational flexibility of
the lipid-free molecule.
Mutations of the central domain. Several naturally occur-
ring mutations in the central domain of apoA-I have been
described (Table 1). However, few of them have been asso-
ciated with clear defects in lipid binding properties. Only
when the secondary structure of the protein was clearly
modified [Lys107 Ý 0, D(146–160)], were impaired lipid-
binding properties observed (76, 77). Interestingly, when
incubated with cells, the mutant D(146–160) was predom-
inantly associated with large HDL (9–20 nm) whereas the
native protein could also form smaller complexes (7.5
nm) (77). ApoA-IMilano (Arg173 Ý Cys), which has been ex-
tensively studied (78–87) also appears to be associated
with size restricted HDL lipoproteins (smaller HDL and
reduced number of HDL subpopulations) as observed in
vitro and in vivo compared to the wild-type apolipoprotein
(82, 85). Apparently, this size restriction is the result of
the dimerization of apoA-I induced by the presence of a
Cys residue in the mutant protein. Although not demon-
strated, the apoA-IMilano dimer may be formed intracellu-
larly before lipidation and generation of HDL particles.
To analyze the role and importance of the central heli-
ces in apoA-I association with lipids, three mutants corre-
sponding to deletions of central a-helices [D(100–143),
D(122–165), D(144–186)] have been produced (61). These
deletions have been designed to characterize the lipid-
binding properties of the central helices and to test the
hypothesis of a possible hinge domain in human apoA-I.
In the resulting mutants, the periodicity of the helices and
the overall secondary structure present in native human
apoA-I was maintained. We have shown that, compared to
a deletion of the C-terminal domain, deletions in the cen-
tral domain of apoA-I have little effect on the kinetics of
association with DMPC (61, 88). Moreover, these central
domain deletion mutants can still associate with cellular
lipids and form lipoprotein particles in vitro (88). These
results therefore suggest that these central helices may not
play an essential role in the initial binding of lipid. How-
ever, the corresponding mutants appear to have a reduced
lipid binding capacity (61), which may indicate that they
are not capable of accommodating varying amounts of
phospholipid. Taken together, these observations support
the hypothesis that the central domain of apoA-I (residues
100–186) is actually responsible for the plasticity of apoA-I
and allows the binding of varying amounts of lipid. This
concept is also compatible with the observations of Durbin
and Jonas (89) that apoA-II can displace the same central
helices of apoA-I from the lipoprotein, a process that facil-
itates apoA-I displacement from HDL. Recent observa-
tions from this laboratory on the role of central helices in
the maturation of HDL in vivo demonstrate conclusively
that the helix formed by residues 100–121 and to a lesser
extent the helix formed by residues 122–143 are very im-
portant in lipid binding. In contrast, the two helices be-
tween residues 144 and 186 contribute little to lipid bind-
ing (90).
Mutations of the C-terminal domain. Very few natural mu-
tations have been described in the C-terminal domain of
apoA-I (Table 1). Funke et al. (91) have described a mu-
tant in which a frameshift mutation leads to a modifica-
tion of residues 203–229 and a smaller mature protein
(229 residues instead of 243). Examination of this patient
revealed corneal opacity and reduced plasma LCAT activity.
However, the presence of a Cys in the modified C-terminal
domain of the protein may also explain the phenotype
since this protein was found to form hetero-oligomers
with apoA-II. A natural Glu198 Ý Lys mutation has been de-
scribed by Strobl et al. (92) but it was not possible to
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firmly establish whether this mutation caused reduced
HDL-C levels. In this case, half of the subjects carrying the
mutation had normal HDL-C levels whereas the other half
had HDL-C below the fifth percentile for age and sex.
This mutant was further characterized in vitro and no par-
ticular impairment in its functional properties could be
demonstrated (76, 93). However, Han et al. (94) have re-
cently identified a new apoA-I mutant (Glu235 Ý 0) that is
associated with low HDL-C levels possibly because of an in-
creased turnover of the mutant protein, which may be due
to a reduced lipid-binding affinity. In support of this view,
studies with rabbits (95, 96) and with transgenic mice (97)
have confirmed the importance of the C-terminal domain
of apoA-I in the formation of HDL lipoproteins. In rabbit
studies, deletion of residues 201–243, 217–243, or 226–
243 (95) and 190–243 (96) markedly increased the rates
of apoA-I catabolism. Furthermore, the C-terminal trun-
cated apoA-I proteins were mostly associated with very
high density lipoprotein (VHDL), which suggests a poor
ability of the mutant apoproteins to associate with lipids
and form mature and fully lipidated HDL. Holvoet et al.
(96) have also shown that replacement of domain 190–
243 with helices of apoA-II (residues 12–77), which has a
higher lipid-binding affinity than apoA-I, could not im-
prove this association. Slightly different results were ob-
served in transgenic mice where the same chimeric apolipo-
protein, apoA-I(1–189)–apoA-II(12–77), could associate
very well with lipids and form large HDL particles (97).
These differences may be related to the genesis of HDL:
rabbit apoA-I that is already associated with rabbit HDL
has to be displaced by the injected apoprotein whereas in
transgenic mice, preformed HDL containing the protein
of interest were directly being studied. Moreover, studies
from Laccotripe et al. (98) suggested that engineered mu-
tants, in which hydrophobic residues of the last helix
were modified, had reduced initial binding to phospho-
lipids. These observations are consistent with our data
and those of others showing that the C-terminal domain
187–243 is necessary for the initial association with lipids
(88, 95, 99, 100). Moreover, we have also shown that the
mutant apoA-ID(187–243) could not associate with cel-
lular lipids and form lipoprotein particles (88). The
C-terminal domain, probably residues 220–241, is in-
volved in the initial association with lipids and in the for-
mation of lipoprotein particles (99, 100).
2. INTERACTION OF APOA-I WITH CELLS
A. Mechanisms of cellular cholesterol efflux
The different steps and mechanism of cellular choles-
terol efflux mediated by apoA-I and HDL have been re-
cently reviewed (101–103). Here the emphasis is placed
on the importance of apoA-I structure in the process.
In diffusional efflux, the rate-limiting step is the desorp-
tion of FC from the plasma membrane. Desorption may
depend on the properties of the cell membrane as noted
by several investigators, who showed that under similar ex-
perimental conditions, the rate of cholesterol efflux varies
widely and depends on the cell type examined (104–106).
In addition, the presence of different pools of cholesterol
and their inter-exchange within the plasma membrane
may affect this process (105, 107, 108). The protein com-
position of HDL (apoA-I/apoA-II ratio) has also been
shown to affect this transfer. The lipid composition of ac-
ceptors may be a key factor in this process since several
studies have shown that the phospholipid (109, 110), and
FC (111, 112) content of HDL could affect cholesterol
flux between cells and lipoproteins. This process appears to
depend mostly on the presence of lipids in HDL since pro-
tein modifications by tetranitromethane or limited proteol-
ysis do not affect this diffusional transfer (113, 114). Large
phospholipid vesicles are also less efficient than HDL
when compared on a phospholipid basis (115).
Contrary to the above, other observations suggest a sig-
nificant role for apoA-I in cholesterol efflux mediated by
passive aqueous phase diffusion. The role of different
apoA-I domains in this process has been examined using
mAbs to apoA-I or by site-directed mutagenesis. The abil-
ity of apoA-I to interact with lipid surfaces suggests a pos-
sible role for its amphipathic a-helices to promote cellular
cholesterol efflux from the plasma membrane. The first
studies performed with mAbs to apoA-I have indicated the
involvement of a central domain in this process (116–
119). Banka, Black, and Curtiss (116) found that antibodies
binding to residues 74–110 could inhibit cholesterol efflux
to HDL. Luchoomun et al. (118) and Sviridov, Pyle, and
Fidge (119) provided evidence for the involvement of
domains around residues 165 and 140–150, respectively. In
a different study, Fielding et al. (117) showed that an epitope
of apoA-I (region 137–144) was more exposed in preb1-
HDL than in other subspecies of HDL. The central domain
was suggested to be much more labile than other domains
and, therefore, could interact more easily with the plasma
membrane to promote cellular cholesterol efflux (108).
However, the effects of mAbs on apoA-I are complex and
not only can they interfere sterically with domains other
than the epitope itself (64), but they can also modify the
secondary structure of the protein (120).
Lipid efflux studies to apoA-I mutants performed by
Gillotte et al. (121) and Sviridov, Pyle, and Fidge (122) in
mouse fibroblasts and HepG2 cells respectively, have
shown that deletions of residues 44–126, 139–170, and
190–243 (121) or residues 222–243, 210–243, 150–243,
and 135–243 (122) had no effect on the ability of lipidated
apoA-I to promote cellular cholesterol efflux. We have re-
cently examined the ability of central domain deletion
mutants of apoA-I to promote cholesterol efflux in LpA-I
from fibroblasts (123). Our results confirm that at least in
normal fibroblast the central domain of apoA-I is not re-
quired for efficient diffusional cholesterol efflux as long as
the mutant protein can associate with phospholipids (123).
A second mechanism, which involves the direct binding
of apoA-I to the cell membrane and causes the transfer of
intracellular cholesterol to the plasma membrane, is called
binding- and translocation-dependent cholesterol efflux.
Whether this transfer is specifically due to apoA-I-cell inter-
action per se or to a transfer of cholesterol between intra-
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cellular pools and the plasma membrane as a response to the
removal of FC from the plasma membrane, remains to
be established. Nevertheless, cell binding of HDL and
intracellular cholesterol transfer are abolished upon
tetranitromethane modification or limited proteolysis of
HDL (113, 114), which demonstrates the importance
of intact apoA-I. Mendez (124) recently demonstrated
that cholesterol efflux to lipid-free apoA-I occurs only with
quiescent (growth-arrested) or cholesterol enriched cells.
Several groups have reported the existence of a specific
receptor for apoA-I (101), one recent candidate being the
scavenger receptor class B type I (SR-BI) (125). The inter-
esting feature of this receptor is that efflux to acceptors
appears to be dependent on their phospholipid content
(126), and thus appears relevant to diffusional efflux. This
suggests that the ability of apoA-I (C-terminal domain) to
bind phospholipid is required for efficient cholesterol
efflux as was suggested by several earlier studies (127).
Sviridov et al. (122), using C-terminal deletion mutants,
have shown that the C-terminal domain (deletion of resi-
dues 222–243, 210–243, 150–243, and 135–243) may be
important in intracellular cholesterol efflux mediated by
apoA-I. However, these authors did not observe any effect
of these deletions on the binding to HepG2 cells. These
findings cannot be simply explained by the presence of a
receptor that mediates cholesterol efflux. Other high af-
finity non-specific cell surface binding sites for apoA-I at
the surface of HepG2 cells may mask the specific binding
to the low affinity binding sites specifically involved in the
transfer of intracellular cholesterol to the plasma mem-
brane. A low binding affinity of apoA-I for cell may be re-
quired in order to allow a rapid release of apoA-I after or
upon acquisition of cellular phospholipid and cholesterol.
B. ApoA-I structure and cellular cholesterol efflux
Only a few studies have characterized the efflux capability
of naturally occurring apoA-I mutants (93), and most
used the plasma lipoproteins formed by the mutant pro-
teins (83, 94, 128, 129). No mutant with a mutation in the
N-terminal domain has been examined (Table 1).
Most of the naturally occurring apoA-I mutants ana-
lyzed correspond to alteration of residues in the central
domain of apoA-I. Three natural variants of apoA-I have
been shown to have a reduced ability to promote cellular
cholesterol efflux. These mutations (Pro165 Ý Arg, (93);
Arg173 Ý Cys, (83)) may affect the secondary and/or ter-
tiary structure of the C-terminal domain of apoA-I. The
substitution Pro165 Ý Arg may result in the elimination of a
b-turn or kink between adjacent helices, which could
modify the accessibility of the C-terminal domain to lipids
and/or cells in the resulting mutant. The Arg173 Ý Cys mu-
tation induces the dimerization of apoA-I through an in-
termolecular covalent cystine crosslink. The monomer
has a decreased lipid binding affinity (130), but the
dimerization alters the conformation of the C-terminal
domain and modifies the lipid binding properties of the
mutant apoproteins (130). The apoA-IMilano dimer has an
increased ability to promote efflux from macrophages
and Fu5AH compared to wild type (131).
In our studies (88, 123), the deletion of central a-heli-
ces had no effect on the ability of apoA-I to promote
either diffusional or specific cellular cholesterol efflux
from normal and cholesterol-loaded fibroblasts, or from
cholesterol-loaded macrophages. However, these results
were obtained in the absence of LCAT and other plasma
factors involved in the metabolism of HDL. In particular,
mutants apoA-ID(122–165) and apoA-ID(144–186) may
display a reduced ability to promote cellular cholesterol
efflux in plasma or in the presence of LCAT alone since
they cannot activate the cholesterol esterification reaction
as efficiently as recombinant apoA-I and apoA-ID(100–143)
(123). In support of this hypothesis, the ability of a natu-
rally occurring apoA-I mutant (Leu141 Ý Arg) to promote
cellular cholesterol efflux was examined with plasma from
subjects carrying this mutation (hemizygote patients)
(128): A reduced cellular cholesterol efflux to plasma was
observed, which may be due to a reduced transfer of cho-
lesterol from preb-HDL to a-HDL. This probably resulted
from the reduced ability of the mutant apoprotein to acti-
vate LCAT (128). Cholesterol esterification may therefore
promote the flux of cholesterol through the HDL pool by
stimulating the formation of cholesteryl esters that are
transferred to apoB-containing lipoproteins by CETP, and
then cleared via the LDL-receptor pathway in the liver
(132).
Cellular cholesterol efflux mediated by two natural vari-
ants with C-terminal mutations (Glu198 Ý Lys, Glu235 Ý 0)
have been examined (93, 94). The first mutation
(Glu198 Ý Lys) was not associated with reduced cholesterol
efflux, however, the other mutation (Glu235 Ý 0) (94) was
accompanied with a 54% decrease in cholesterol efflux
from cholesterol-loaded mouse peritoneal macrophages.
We have also observed that deletion of residues 187–243
of apoA-I was associated with a markedly reduced ability
of the mutant apoprotein to promote cellular cholesterol
efflux from cholesterol-loaded macrophages (88). The
mutant was also unable to form lipoproteins upon incuba-
tion with the cells and this property was associated with a
reduced kinetic of association with DMPC (88). Interest-
ingly, the natural apoA-I mutant Glu198 Ý Lys did not ap-
pear to have a reduced ability to associate with lipids (76).
This suggests that the ability of apoA-I to promote specific
cholesterol efflux from macrophages depends on a func-
tional C-terminal lipid binding domain.
Simple diffusional transfer between the plasma mem-
brane and the apoA-I-containing lipoprotein acceptor (i.e.,
HDL) appears to require the presence of amphipathic
a-helices. Diffusional cholesterol efflux to an amphi-
pathic peptide depends on the peptide lipid affinity and
ability to retain cholesterol molecules (115, 127). These
concepts are supported by our observations that apoA-I
mutants (deletion of the central domain 100–143, 122–
165, 144–186) that can associate with lipid (61) can also,
in the lipid-bound form (Lp2A-I), promote cellular choles-
terol efflux (88, 123). Specific or translocation-dependent
efflux involves the interaction of lipid-free apoA-I with
specific cell surface binding sites, followed by the transfer
of intracellular cholesterol from an ACAT-accessible pool
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to the plasma membrane and subsequent transfer to the
donor. The first step also appears to be mediated by am-
phipathic a-helices since synthetic peptides with affinity
for lipids can mediate this transfer (127, 133). In this pro-
cess, apoA-I may interact with specific plasma membrane
domains such as caveolae (enriched in FC and sphingo-
myelin) and subsequent transfer of FC and phospholipid
to the apoprotein may generate preb-HDL (134). In
agreement with this proposed mechanism, the reduced
affinity of peptides for the lipid surface is associated with
a reduced ability to promote cellular cholesterol efflux
(127, 133). The C-terminal domain of apoA-I may there-
fore play a major role in this interaction of the lipid-free
apoprotein with the cell. Our data showing that apoA-
ID(187–243) displays both a reduced cell surface binding
and reduced cellular cholesterol efflux from cholesterol-
loaded macrophages agree with this model (88). In con-
trast, this mutant displays similar binding and efflux with
cholesterol-loaded fibroblasts. The difference in cell spec-
ificity may be due both to the lower cholesterol content of
cholesterol-loaded fibroblasts and to the specific cell sur-
face properties of cholesterol-loaded macrophages (88).
That the N-terminal domain (44–65) is important to the
initial binding of apoA-I to lipid (13) would suggest that it
should also contribute to specific efflux (13). Further
studies of apoA-I with mutations in this domain would
help to determine if this domain is also involved in this
important function of apoA-I. The recent characterization
of mutations affecting the ABC-1 gene in Tangier disease
and hypoalphalipoproteinemia (135–137) has shown the
importance of this integral cell membrane protein in cho-
lesterol efflux. Lawn et al. (138) have reported its pres-
ence on the plasma membrane, suggesting that it may di-
rectly participate in the binding of apoA-I. Differences in
expression levels of ABC-1 may also account for the cell
specificity in lipid efflux. Other recent studies have dem-
onstrated the role of ABC1 in the regulation of cellular
cholesterol efflux and its involvement in Tangier disease
(138–140).
3. APOA-I AND THE ACTIVATION OF 
LECITHIN:CHOLESTEROL ACYL TRANSFERASE
The LCAT glycoprotein (EC 2.3.1.43), consisting of 416
amino acids, displays two activities: a phospholipase A2 ac-
tivity, since it can hydrolyze the sn-2 fatty acid from phos-
phatidylcholine, and an acyltransferase activity, since it
can transfer the fatty acid to FC and form CE. A detailed
analysis of LCAT has been previously reviewed (141–143).
A. LCAT activation
Although LCAT may be able to bind lipids directly, op-
timum reaction requires activation by one of the ex-
changeable apoproteins. ApoA-I was the first described ac-
tivator of LCAT (144) and is its most potent in vivo
activator (141). This reaction requires at least three steps.
First, LCAT binds to the substrate (HDL) and/or the acti-
vator, and in a second step, LCAT hydrolyzes the fatty acid
at the sn-2 position of a phospholipid. The third and final
step is the transesterification of cholesterol and concomi-
tant release of CE.
The lipid composition of HDL can affect the ability of
apoA-I to activate cholesterol esterification by LCAT. In
several studies, it has been suggested that this effect was
directly related to a modification of apoA-I stability and/or
conformation or to the ability of LCAT to bind substrates
(37, 40, 145–148). In particular, Sparks et al. (51, 149)
have suggested a role for the surface charge properties of
apoA-I in its interaction and ability to activate LCAT.
The mechanism of activation is not simple, as LCAT can
hydrolyze small soluble substrates in the absence of apo-
lipoproteins and can directly interact with lipid interfaces,
although with reduced affinity as compared to apopro-
teins (142). Numerous investigations have demonstrated
the effect of varying the HDL apolipoprotein-lipid compo-
sition on the LCAT reaction (37, 51, 89, 145, 146, 148,
149). These changes have been in part attributed to modi-
fication of the charge and conformation of apoA-I, which
suggests that in vivo, both the apolipoprotein and lipid
composition of HDL can modulate the interaction between
apoA-I and LCAT (37, 51, 149). In this context, several
studies have shown that small complexes (low phospho-
lipid/A-I molar ratio) were more efficient in activating
LCAT (145, 149). In that case, the increased reactivity was,
in part, associated with a change in the accessibility of the
N-terminal and central domains of apoA-I that may be in
close contact in the tertiary structure (64, 149). Other lipids
such as cholesterol (increases LCAT activity with in-
creased cholesterol content) or sphingomyelin and phos-
phatidylcholine (both reduce LCAT activation) may affect
differently these domains of apoA-I (51, 89, 148, 149).
The conformational changes of apoA-I that are associated
with very specific lipid compositions appear to allow the
interaction of LCAT, either directly with the lipid phase or
through apoA-I.
Other apolipoproteins can also activate the LCAT reaction
but below 20% of that observed for apoA-I (150, 151).
Since the presence of amphipathic a-helices is required
but not sufficient to activate LCAT efficiently, a specific
domain of apoA-I may be responsible for this function.
Studies designed to examine the sequence involved have
been performed using synthetic peptides, CNBr fragments
of apoA-I and, finally, site-directed mutagenesis. Studies
with peptides suggested that despite a high affinity for lipids,
the C-terminal domain could not activate LCAT whereas
the region 148–185 could bind and activate the enzyme
(152). Other synthetic peptides with a high amphipathic
character, but no homology to the apoA-I sequence, could
also activate LCAT (153, 154). Anantharamaiah et al.
(155) have constructed a peptide corresponding to a dimer
of the consensus amino acid sequence obtained for the
eight 22-mer predicted a-helices of apoA-I. This peptide
gave maximal LCAT activation only as a dimer and when
residue 13 of the helix was glutamic acid. These results
suggested that activation of LCAT was depending on a
large domain of apoA-I located within residues 66–121.
Inhibition of cholesterol esterification in the presence of
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mAbs against apoA-I also suggested that a rather large
domain corresponding to residues 95–175 could be in-
volved in LCAT activation. Moreover, Meng et al. (156)
demonstrated that a mAb recognizing the N-terminal
domain of apoA-I (mAb 4H1 reacting with residues 2–8)
could enhance cholesterol esterification. This was only ob-
served in small cholesterol-rich Lp2A-I particles, where
the N-terminal epitope shares structural relationships with
specific central domain epitopes. However as noted above,
the effects of mAbs on apoA-I are complex as antibodies
not only interfere sterically with other domains (64) but
can also modify the structure of the protein (120).
Recent studies have now clearly established that region
144–186 is the LCAT activator domain of apoA-I (123,
157–160). After alignment of these helices with other LCAT
activating peptides, we have proposed an LCAT activating
motif (123) (Fig. 6). This model is also supported by in
vivo studies of naturally occurring apoA-I mutants (Table
1, Fig. 6 and see below). Interestingly as noted earlier, the
central region of apoA-I may also be involved in the spe-
cific binding of cholesterol in HDL. This domain could
therefore allow the presentation of cholesterol to LCAT.
B. ApoA-I mutants and identification of domains
involved in LCAT activation
Numerous groups have investigated the relationship
between LCAT activation and apoA-I structure and/or
conformation (51, 142, 145, 149). Recent studies have
identified the central and C-terminal domains of apoA-I
in the activation of LCAT.
Among the natural mutants of apoA-I corresponding to
modification of residues in the N-terminal domain, only a
few have been studied for their ability to activate LCAT and
none were shown to negatively affect cholesterol esterifica-
tion (Table 1) (76). A study of the site-directed engineered
mutant, apoA-ID(1–43), suggested that this mutant had
only a slightly reduced ability to activate the LCAT reaction
(31). A large body of data obtained with natural and syn-
thetic mutants firmly shows that the central domain 144–
186 is involved in this reaction (123, 157, 158, 160, 161).
Since this central domain may interact with the N-terminal
domain (54, 64), a specific interaction between these
two domains may contribute to the stabilization of lipid-
associated apoA-I and subsequently to the efficient esterifi-
cation of FC by LCAT. Several natural variants with defec-
tive LCAT activation properties (Lys107 Ý 0, Leu141 Ý Arg,
D(146–160), Arg151Ý Cys, Val156Ý Glu, Leu159Ý Arg, Pro165Ý
Arg, Arg173Ý Cys) have been identified and most of them
correspond to mutations in the central domain 144–186
(Table 1). Other mutations (Lys107Ý 0, Leu141Ý Arg) may
have a direct effect on the conformation of this central do-
main and indirectly affect the ability of apoA-I to activate
LCAT (149, 156, 162, 163).
The mechanism by which apoA-I activates LCAT is still
unknown but may involve a direct interaction between
apoA-I helices and residues 152–169 of LCAT. Positively
charged residues present in both helices 144–165 and
166–186 may interact with negatively charged residues
found on this LCAT helix. Mutagenesis studies of LCAT
by Wang et al. (164) have shown that Glu 154, 155, and
165 are not important for LCAT activity but may be in-
volved in the binding of cholesterol. The region 151–174
of LCAT may therefore indirectly interact with apoA-I
through the binding with HDL cholesterol, a process that
may result in a conformational change of LCAT and its ac-
tivation. The lower lipid binding affinity of apoA-I central
helices (residues 144–186) (13) allows their displacement
by apoA-II (89) and may also favor their displacement and
interaction with the LCAT helix (residues 152–169).
Interestingly, mutations of positively charged residues
in these apoA-I helices usually result in decreased LCAT
activation (84, 165). In small discoidal LpA-I (except
those rich in cholesterol (165)), where these central helices
may not interact completely with lipids, LCAT activation
appears to be most efficient, possibly because of an en-
hanced accessibility to the lipid interface and to the cen-
tral domain of apoA-I (149). In support of this model, an
increase in the negative surface charge of the Lp2A-I is as-
sociated with increased LCAT reactivity (149). In HDL
complexes, where the lipid species have little effect on the
lipoprotein surface charge, it appears that a modification
of the surface charge properties is primarily due to a
change in apoA-I conformation (22, 149, 166, 167). LCAT
activity may therefore be a function of the exposure of
apoA-I charged residues in these lipoproteins. Several
studies have shown a direct effect of the surface charge of
LpA-I on the structure and function of lipoproteins (22,
51, 149, 166–168). ApoA-I conformation is affected by
HDL lipid composition and is the major determinant of
HDL charge, even if charged lipids (phosphatidylinositol,
phosphatidylserine) can directly contribute to the nega-
tive charge of HDL. Different lipids can also have differ-
ent effects on the stability of apoA-I in HDL (22, 51, 149,
166). NMR and mAb immunoreactivity studies have also
implicated a specific domain of apoA-I in the binding of
FC in HDL (39, 64). This binding, which occurs around
residue 144 of apoA-I, may also be responsible for the spe-
cific changes in the charge of HDL containing FC (166).
The C-terminal domain of apoA-I was suggested to be
Fig. 6. Alignment of the LCAT activator peptide with amino acids
143–164, 165–186 of apoA-I. The residues highlighted in bold re-
flect common or conserved amino acids that may be required for
LCAT activation. A putative LCAT activation motif, which reflects
common or conserved residues between the three aligned se-
quences is proposed. Lowercase letters (d, r, l, e, and k) indicate
conserved residues (the preponderant residue is shown) and the
symbol C denotes the presence of hydrophobic residues in the
three aligned sequences. Mutations of residues indicated by arrows
have been identified in patients with reduced HDL levels and may
result in lower LCAT activity (see text for details).
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involved in LCAT activation in several studies (98, 157,
158) but it now appears that this observation was due to
defective lipid-binding properties of the mutants. In these
assays, lipid vesicles were incubated with apoA-I mutants
and as the C-terminal mediates the initial binding, these
mutants could not interact properly with lipids and there-
fore activate LCAT. This has been confirmed by Dhoest et
al. (160) who showed that replacement of the carboxyl
terminal (190–243) by residues 12–75 of apoA-II restores
the lipid binding properties of the protein but does not
change its ability to activate cholesterol esterification. Be-
cause apoA-II is not so efficient as apoA-I in activating
the reaction mediated by LCAT (169), it follows that
the C-terminal domain of apoA-I is not crucial for this ac-
tivity. This notion is supported by the work of Han et al.
(94) who showed that a patient carrier for the mutation
apoA-I Glu235 Ý 0 had normal plasma LCAT activity.
C. Physiological significance of apoA-I 
activation of LCAT
The N-terminal domain (residues 1–43) may be impor-
tant for the stability of the protein in the lipid-free state and
indirectly modulate its interaction with LCAT. The central
domain (100–186) has a function in the regulation of the
interaction with phospholipid and is responsible for the
plasticity of the molecule by allowing its association with
varying amounts of phospholipid. The domain formed by
residues 100–143 and within it by the helix containing resi-
dues 100–121 has a very significant role in the binding of
phospholipids, both in vitro (61) and in vivo (90). Beside
this role, part of the central domain, which includes resi-
dues 144–186, forms the site involved in LCAT activation
(123). However, efficient LCAT activation also requires a
certain affinity for phospholipid that is contributed by the
C-terminal domain (187–243), and within it, probably by
the last helix (220–241). In addition, the lipid binding affin-
ity of the C-terminal domain appears crucial for the ability
of apoA-I to promote cholesterol efflux from cholesterol-
loaded macrophages, a process, which may require the effi-
cient binding of the apoA-I C-terminal domain to the cell.
As indicated in Table 1, mutations in the LCAT activating
domain of apoA-I result in reduced HDL-C levels, but are
not necessarily associated with increased risk of CHD, possi-
bly because LCAT can still esterify LDL-derived cholesterol
and possibly because a functional efflux capacity is more
important than a functional LCAT activation. Additional
risk factors (e.g., elevated LDL-C, obesity) may be required
to observe an increase in CHD as observed by Miccoli et al.
(170). However, cholesterol esterification may promote the
flux of cholesterol through the HDL pool by stimulating
the formation of cholesteryl esters that are transferred by
CETP to apoB-containing lipoproteins (128). Nevertheless,
it is intriguing that almost all identified mutations that af-
fect the LCAT activating domain of apoA-I, are associated
with reduced HDL-C. However, the technique used in
screening for apoA-I mutations has relied, in most cases, on
the presence of a charge modification of the mutant pro-
tein. Therefore, the screening procedure may not have de-
tected mutations that did not affect the protein charge.
4. CONCLUSIONS
Much remains to be understood about apoA-I structure–
function relationships. More refined mutagenesis strate-
gies are still required to identify the specific functions of
apoA-I domains. The mechanism by which apoA-I associ-
ates with phospholipid has to be examined in more detail
and studies with apoA-I that contains point mutations of
hydrophobic and charged residues in helices, should pro-
vide additional insight into the mechanism of apoA-I asso-
ciation with lipids. The role of the N-terminal domain
(residues 1–43) in the lipid-free as in the lipid-bound
forms has not been clearly identified; point mutations of
specific charged residues may resolve this question. The
mechanism of LCAT activation by apoA-I has to be further
characterized, such as the functional identification of spe-
cific apoA-I residues involved.
Several major unresolved questions remain in the elucida-
tion of apoA-I structures either in lipid-free or lipid-bound
forms. Is the belt structure prevalent for lipid-bound apoA-
I? Does more than one structure exist for apoA-I in differ-
ent species of lipoproteins? What structural rearrange-
ment accounts for the change of the protein charge in the
preb- and a-HDL forms?
In vivo studies of apoA-I mutants (natural mutants in
human, in transgenic or adenovirus-infected animals) will
also help to identify the mechanisms by which apoA-I par-
ticipates in reverse cholesterol transport. The recent identi-
fication of the gene responsible for Tangier disease (135–
137) and the recent demonstration that cubilin binds
apoA-I and mediates its re-absorption by the kidney proxi-
mal tubule (171) have opened new avenues for the study
of apoA-I metabolism and the regulation of HDL levels.
The domain specificity for apoA-I interaction in these
pathways still has to be established.
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